Drug Profile
Zenocutuzumab - Merus
Alternative Names: HER3 x HER2 Biclonics®; MCLA-128; Zeno; Zenocutuzomab - MerusLatest Information Update: 08 Mar 2024
Price :
$50
*
At a glance
- Originator Merus
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists; ERBB-3 receptor antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Breast cancer; Non-small cell lung cancer; Prostate cancer
- Phase I/II Solid tumours
Most Recent Events
- 05 Mar 2024 Merus plans to submit BLA for zenocutuzumab for Non-small cell lung cancer and Pancreatic cancer
- 23 Oct 2023 Merus plans to submit BLA for zenocutuzumab for Solid tumours
- 23 Oct 2023 Updated interim efficacy and adverse events data from the I/II eNRGy trial and Early Access Program (EAP) in Solid tumours presented at the European Society for Medical Oncology Congress 2023 (ESMO-2023)